Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million. What happened According to its SEC filing dated February 17, 2026, BVF fully liquidated its stake in Protagonist Therapeutics (NASDAQ:PTGX), selling 2,560,916 shares. The quarter-end position value decreased by $170.12 million. What else to know BVF sold out of Protagonist Therapeutics. Top holdings after the filing: NASD ...

Core Insights - The broader market has performed well, with the SPDR S&P 500 ETF Trust up approximately 16% year-to-date, but a notable shift in leadership is occurring within the industrials sector, indicating potential capital rotation and outperformance into year-end and beyond [3] Sector Performance - The Industrial Select Sector SPDR Fund (XLI) is up about 19% year-to-date, slightly ahead of the S&P 500, with a recent monthly gain of 3.28% compared to the broader market's 1.29% [4] - XLI has broken out of a multi-month consolidation, which is a technical indicator that may precede sustained sector leadership if the breakout holds [4][5] Technical Analysis - XLI had been trading between $150 and $155 since July but recently broke decisively above $155, signaling a potential trend shift [5] - The ETF has experienced 4.9% positive flows over the past three months, indicating improving investor sentiment and capital movement into the sector [5] Key Holdings - XLI includes major industrial companies such as GE Aerospace, Caterpillar, RTX Corp., Boeing, Union Pacific, and Uber Technologies, providing diversified exposure to the strengthening industrial sector [6] Sector Leaders - GE Vernova and RTX are highlighted as sector leaders, both showing substantial year-to-date gains and fresh breakouts supported by improving fundamentals and bullish sentiment [7]